Treatment of female infertility with recombinant human luteinising hormone: is there a benefit over other available drugs?

Bibliography

• STOKMAN PG, DE LEEUW R, VAN DEN WIJNGAARD HA et al.: Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil. Steil] (1993) 60:175–178.
   Google Scholar
• CHANNING CP, KAMMERMAN S: Binding of gonadotropins to ovarian cells. Biol. Reprod. (1974) 10:179–198.
   PubMed Web of Science ®Google Scholar
• MARSH JM: The role of cyclic AMP in gonadal function. Adv. Cyclic Nucleotide Res. (1975) 6:137–199.
   PubMedGoogle Scholar
• RICHARDS JS, JAHNSEN T, HEDIN L et al.: Ovarian follicular development: from physiology to molecular biology.Recent Frog. Horm. Res. (1987) 43:231–276.
   PubMedGoogle Scholar
• MENON KM, GUNAGA KP: Role of cyclic AMP in reproductive processes. Fern]. Stern. (1974) 25:732–750.
   PubMedGoogle Scholar
• LAMPRECHT SA, ZOR U, TSAFRIRI A, LINDNER HR: Action of prostaglandin E2 and of luteinising hormone on ovarian adenylate cyclase, protein kinase and ornithine decarboxylase activity during postnatal development and maturity in the rat. J. Endocrina (1973) 57:217–233.
   PubMedGoogle Scholar
• MARSH JM: The role of cyclic AMP in gonadal steroidogenesis. Biol. Reprod. (1976) 14:30–53.
   PubMed Web of Science ®Google Scholar
• CHANNING CP, VILLEE CA: Stimulation of cholesterol metabolism in the luteinized rat ovary by luteinising hormone. Biochim. Biophys. Acta (1966) 127:1–17.
   PubMedGoogle Scholar
• ARMSTRONG DT, LEE TP, MILLER LS:Stimulation of progesterone biosynthesis in bovine corpora lutea by luteinising hormone in the presence of an inhibitor of cholesterol synthesis. Biol. Reprod. (1970) 2:29–36.
   PubMedGoogle Scholar
• SHERIZLY I, GALIANI D, DEKEL N: Regulation of oocyte maturation: communication in the rat cumulus-oocyte complex. Hum. Reprod. (1988) 3:761–766.
   PubMed Web of Science ®Google Scholar
• BEHRMAN HR, AMSTRONG DT: Cholesterol esterase stimulation byluteinising hormone in luteinized rat ovaries. Endocrinology (1969) 85:474–480.
   PubMedGoogle Scholar
• ROBINSON J, STEVENSON PM, BOYD GS, ARMSTRONG DT: Acute in vivo effects on HCG and LH on ovarian mitochondrial cholesterol utilization. Ma Cell. Endocrinol (1975) 2:149–155.
   PubMedGoogle Scholar
• CARON MG, GOLDSTEIN S,SAVARD K, MARSH JM: Protein kinase stimulation of a reconstituted cholesterol side chain cleavage enzyme system in the bovine corpus luteum.,/ Biol. Chem. (1975) 250:5137–5143.
   PubMed Web of Science ®Google Scholar
• FEVOLD HL: Synergism of follicle stimulating and luteinising hormones in producing estrogen secretion. Endocrinology(1941) 28:33–36.
   Google Scholar
• SHORT RV: Steroids in the follicular fluid and the corpus luteum of the mare. A 'two-cell type' theory of ovarian steroid synthesis. Endocrinol (1962) 24:59–63.
   Google Scholar
• RYAN KJ, PETRO Z, KAISER J: Steroid formation by isolated and recombined ovarian granulosa and tehcal cells. J. Endocrinol Metab. (1968) 28:355–358.
   PubMed Web of Science ®Google Scholar
• COUZINET B, LESTRAT N, BRAILLY S, FOREST M, SCHAISON G: Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency. I. Gin. Endocrinol Metab. (1988) 66:552–556.
   PubMed Web of Science ®Google Scholar
• •One of the first clinical studies confirming the 'two-cell, two gonadotropin' theory.
   Google Scholar
• SHOHAM Z, BALEN A, PATEL A, JACOBS HS: Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertid. Sten7. (1991) 56:1048–1053.
   PubMed Web of Science ®Google Scholar
• THE EUROPEAN RECOMBINANT HUMAN LH STUDY GROUP: Recombinant human luteinising hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. I. Cliii. Endocrinol Metab. (1998) 83:1507–1514.
   PubMed Web of Science ®Google Scholar
• CHABBERT-BUFFET N, BOUCHARD P: The normal human menstrual cycle.Rev Endocrinol Metab. Disord. (2002) 3:173–183.
   PubMedGoogle Scholar
• •An extensive review of the physiology of the menstrual cycle.
   Google Scholar
• SEIBEL MM, SMITH DM, LEVESQUE L, BORTEN M, TAYMOR ML: The temporal relationship between the luteinising hormone surge and human oocyte maturation. Am. J. Obstet. Cynecol (1982) 142:568–572.
   PubMedGoogle Scholar
• ITSKOVITZ-ELDOR J, LEVRON J, KOL S: Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimulation syndrome. Gin. Obstet. Cynecol (1993) 36:701–710.
   Google Scholar
• PELUSO JJ: Role of the amplitude of the gonadotropin surge in the rat. Fertid. Sten7. (1990) 53:150–154.
   PubMedGoogle Scholar
• HOFF JD, QUIGLEY ME, YEN SS: Hormonal dynamics at midcycle: a reevaluation. J. Cliii. Endocrinol Metab. (1983) 57:792–796.
   PubMed Web of Science ®Google Scholar
• FRITZ MA, MCLACHLAN RI, COHEN NL et al.: Onset and characteristics of the midcycle surge in bioactive and immunoactive luteinising hormone secretion in normal women: influence of physiological variations in periovulatory ovarian steroid hormone secretion. Clin. Endocrinol Metab. (1992) 75:489–493.
   Google Scholar
• CARGILLE CM, ROSS GT, YOSHIMI T: Daily variations in plasma follicle stimulating hormone, luteinising hormone and progesterone in the normal menstrual cycle. J. Cliii. Endocrinol Metab. (1969) 29:12–19.
   PubMed Web of Science ®Google Scholar
• SHOHAM Z, SCHACTER M, LOUMAYE E et al: The luteinising hormone surge-the final stage in ovulation induction: modern aspects of ovulation triggering. Fern]. Stern. (1995) 64:237–251.
   PubMed Web of Science ®Google Scholar
• •Compiles updated information regarding gonadotropin secretion, specifically the physiology of the mid-cycle LH surge, in natural cycles and under various ovulation induction protocols.
   Google Scholar
• TRINCHARD-LUGAN I, KHAN A, PORCHET HC, MUNAFO A: Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female
   Google Scholar
• Expert Op/n. Pharmacother. (2003) 4(11)volunteers. Reprod. Biomed. Online (2002) 4:106–115.
   Google Scholar
• LE COTONNEC JY, LOUMAYE E, PORCHET HC, BELTRAMI V, MUNAFO A: Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinising hormone and recombinant human follicle-stimulating hormone. Feral. Stern. (1998) 69:201–209.
   PubMed Web of Science ®Google Scholar
• LE COTONNEC JY, PORCHET HC, BELTRAMI V, MUNAFO A: Clinical pharmacology of recombinant human luteinising hormone: Part II. Bioavailability of recombinant human luteinising hormone assessed with an immunoassay and an in vitro bioassay. Feral. Stern. (1998) 69:195–200.
   Google Scholar
• LE COTONNEC JY, PORCHET HC, BELTRAMI V, MUNAFO A: Clinical pharmacology of recombinant human luteinising hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinising hormone. Feral. Stern. (1998) 69:189–194.
   Google Scholar
• DAMEWOOD MD, SHEN W, ZACUR HA et al: Disappearance of exogenously administered human chorionic gonadotropin. Feral. Stern. (1989) 52:398–400.
   PubMed Web of Science ®Google Scholar
• BRAUNSTEIN GD, BLOCH SK, RASOR JL, WINIKOFF J: Characterization of antihuman chorionic gonadotropin serum antibody appearing after ovulation induction. I. Clin. Endocrinol Metab. (1983) 57:1164–1172.
   PubMed Web of Science ®Google Scholar
• KYLE CV, GRIFFIN J, JARRETT A, ODELL WD: Inability to demonstrate an ultrashort loop feedback mechanism for luteinising hormone in humans. Clin. Endocrinol Metab. (1989) 69:170–176.
   Google Scholar
• NADER S, BERKOWITZ AS: Endogenous luteinising hormone surges following administration of human chorionic gonadotropin: further evidence for lack of loop feedback in humans. I. Assist. Reprod. Genet. (1992) 9:124–127.
   PubMedGoogle Scholar
• DEMOULIN A, DUBOIS M, GERDAY C et al.: Variations of luteinising hormone serum concentrations after exogenous human chorionic gonadotropin administration during ovarian hyperstimulation. Feral Stern. (1991) 55:797–804.
   PubMedGoogle Scholar
• GOLAN A, RON-EL R, HERMAN A et al.: Ovarian hyperstimulation syndrome:an update review. Obstet. Gynecol. Surv. (1989) 44:430–440.
   PubMedGoogle Scholar
• GIDLEY-BAIRD AA, O'NEILL C, SINOSICH MJ et al.: Failure of implantation in human in vitro fertilisation and embryo transfer patients: the effects of altered progesterone/estrogen ratios in humans and mice. Feral. Stern. (1986) 45:69–74.
   Google Scholar
• FORMAN R, FRIES N, TESTART J et al.:Evidence for an adverse effect of elevated serum oestradiol concentrations on embryo implantation. Feral. Stern. (1988) 49:118–122.
   PubMed Web of Science ®Google Scholar
• ABBASI R, KENIGSBERG D, DANFORTH D, FALK RJ,HODGEN GD: Cumulative ovulation rate in human menopausal/human chorionic gonadotropin-treated monkeys: `step-up' versus 'step-down' dose regimens.Feral Stern. (1987) 47:1019–1024.
   PubMedGoogle Scholar
• RANASINGHE L: Recombinant technology in medical research and therapeutics. Ceylon Med. (1983) 28:57–61.
   PubMedGoogle Scholar
• ARUFFO A, SEED B: Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Nati Acad. Sci. USA (1987) 84:8573–8577.
   PubMed Web of Science ®Google Scholar
• JULIUS D, MACDERMOTT AB, AXEL R, JESSELL TM: Molecular characterization of a functional cDNA encoding the serotonin lc receptor. Sdence (1988) 241:558–564.
   Google Scholar
• SIMPSON AJ, WALKER T, TERRY R: An introduction to recombinant DNA technology. Parasitology (1986) 92(Suppl.):S7–S14.
   Google Scholar
• FONG Y, MOLDAWER LL, LOWRY SF: Experimental and clinical applications of molecular cell biology in nutrition and metabolism. Parenter. Enteral Num. (1992) 16:477–486.
   PubMed Web of Science ®Google Scholar
• PORCHET HC, LE COTONNEC JY, NEUTEBOOM B, CANALI S,ZANOLO G: Pharmacokinetics of recombinant human luteinising hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinising hormone. j Clin. Endocrinol Metab. (1995) 80:667–673.
   PubMed Web of Science ®Google Scholar
• SHOHAM Z, INSLER V: Recombinant technique and gonadotropins production: new era in reproductive medicine.Feral Stern. (1996) 66:187–201.
   PubMedGoogle Scholar
• •A review of the current knowledge regarding rDNA technology and its safety and efficacy in relation to recombinant gonadotropin.
   Google Scholar
• HOWLES CM: Genetic engineering of human FSH (Gonal-F). Hum. Reprod. Update (1996) 2:172–191.
   PubMedGoogle Scholar
• PIERCE JG, PARSONS TF: Glycoprotein hormones: structure and function. Ann. Rev Biochem. (1981) 50:465–495.
   PubMed Web of Science ®Google Scholar
• KEUTMANN HT, DAWSON B, BISHOP WH, RYAN RJ: Structure of human luteinising hormone alpha subunit. Endocr: Res. Commun. (1978) 5:57–70.
   PubMed Web of Science ®Google Scholar
• PAREKH RB, PATEL TP: Comparing the glycosylation patterns of recombinant glycoproteins. Trends Biotech. (1992) 10:276–280.
   PubMedGoogle Scholar
• ULLOA-AGUIRRE A, ESPINOZA R, DAMIAN-MATSUMURA P,CHAPPEL SC: Immunological and biological potencies of the different molecular species of gonadotrophins. Hum. Reprod. (1988) 3:491–501.
   PubMed Web of Science ®Google Scholar
• GREEN ED, BAENZIGER JU: Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. I. Structural elucidation of the sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones. J. Biol. Chem. (1988) 263:25–35.
   Google Scholar
• NAYLOR SL, CHIN WW,GOODMAN HM et al.: Chromosome assignment of genes encoding the alpha and beta subunits of glycoprotein hormones in man and mouse. Somatic Cell Genet. (1983) 9:757–770.
   Google Scholar
• VANDE WIELE RL, BOGUMIL J, DYRENFURTH I et al: Mechanisms regulating the menstrual cycle in women. Recent Frog. Horm. Res. (1970) 26:63–103.
   PubMedGoogle Scholar
• RABAU E, DAVID A, SERR DM, MASHIACH S, LUNENFELD B: Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am.j Obstet. Gynecol (1967) 98:92–98.
   PubMed Web of Science ®Google Scholar
• BAER G, LOUMAYE E: Comparison of recombinant human luteinising hormone (rhLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology. Curr: Med. Res. Opin. (2003) 19:83–88.
   PubMedGoogle Scholar
• BROWN JB: Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust. NZ I Obstet. Gynaecol (1978) 18:46–54.
   PubMed Web of Science ®Google Scholar
• SHOHAM Z, MANNAERTS B, INSLER V, COELINGH-BENNINK H: Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Feral Stern. (1993) 59:738–742.
   PubMed Web of Science ®Google Scholar
• SCHOOT DC, HARLIN J, SHOHAM Z et al.: Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women. Hum. Reprod. (1994) 9:1237–1242.
   PubMed Web of Science ®Google Scholar
• SCHOOT DC,COELINGH BENNINK HJ, MANNAERTS BM et al: Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. J. Chit. Endocrinol Metab. (1992) 74:1471–1473.
   PubMed Web of Science ®Google Scholar
• BALASCH J, FABREGUES F: Pregnancy after administration of high dose recombinant human LH alone to support final stage of follicular maturation in a women with a long-standing hypogonadotropic hypogonadism.Reprod. Biomed. Online (2003) 6:427–431.
   PubMedGoogle Scholar
• BALASCH J, FABREGUES F, CASAMITJANA R, PENARRUBIA J, VANRELL JA: A pharmacokinetic and endocrine comparison of recombinant follicle-stimulating hormone and human menopausal gonadotrophin in polycystic ovary syndrome. Reprod. Biomed. Online (2003) 6:296–301.
   PubMedGoogle Scholar
• PORTER RN, SMITH W, CRAFT IL, ABDULWAHID NA, JACOBS HS: Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet (1984) 2:1284–1285.
   PubMed Web of Science ®Google Scholar
• LOUMAYE E, ENGRAND P,HOWLES CM, O'DEA L: Assessment of the role of serum luteinising hormone and oestradiol response to follicle-stimulating hormone on in vitro fertilisation treatment outcome. Feral Stern. (1997) 67:889–899.
   PubMed Web of Science ®Google Scholar
• SILLS ES, LEVY DP, MOOMJY M, MCGEE M, ROSENWAKS Z: A prospective, randomised comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinising hormone in in-vitro fertilisation. Hum. Reprod. (1999) 14:2230–2235.
   PubMedGoogle Scholar
• BEN-AMOR A-F ON BEHALF OF THESTUDY GROUP: The effect of luteinisinghormone administered during late follicular phase in normo-ovulatory women undergoing in vitro fertilisation. Hum. Reprod. (2000) 15:46 (Abstract).
   Google Scholar
• MARRS R, MELDRUM D, MUASHER S, SCHOOLCRAFT W, WERLIN L, KELLY E: Does the addition of LH have a benefit for patients of advanced reproductive age undergoing ART? A randomised comparative trial of recombinant human FSH (Gonal-F) alone or in combination with recombinant human LH from day 6 of treatment. Reprod. Biomed. Online (2003) (In Press).
   Google Scholar
• IMTHURN B, PIAZZI A, LOUMAYE E: Recombinant human luteinising hormone to mimic mid-cycle LH surge.Lancet (1996) 348:332–333.
   PubMedGoogle Scholar
• Human recombinant luteinising hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilisation procedures: results of a multi-centre double-blind study. j. Chit. Endocrinol Metab. (2001) 86:2607–2618.
   PubMedGoogle Scholar
• BALASCH J, HOWLES CM: GnRH agonist protocols: which one to use? In: Female Infertility Therapy; Current Practice. Shoham Z, Howles CM, Jacobs HS (Eds), Martin Dunitz, London, UK (1999):189–201.
   Google Scholar
• CHRISP P, GOA KL: Nafamlin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs (1990) 39:523–551.
   Google Scholar
• LISI F, RINALDI L, FISHEL S et al: Use of recombinant LH in a group of unselected IVF patients. Reprod. Biomed. Online (2002) 5:104–108.
   PubMedGoogle Scholar
• LISI F, RINALDI L, FISHEL S et al: Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod. Biomed. Online (2001) 3:190–194.
   PubMedGoogle Scholar
• ESPOSITO MA, BARNHART KT, COUTIFARIS C, PATRIZIO P: Role of periovulatory luteinising hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Feral Stern. (2001) 75:519–524.
   PubMed Web of Science ®Google Scholar
• LOUMAYE E: Do all women need LH for ovarian stimulation?Ben-RafaelZ, Frydman R, Shoham Z (Eds), Monduzzi Publisher, Bologna, Italy (2001):9–15.
   Google Scholar
• WESTERGAARD LG, LAURSEN SB, ANDERSEN CY: Increased risk of early pregnancy loss by profound suppression of luteinising hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum. Reprod. (2000) 15:1003–1008.
   PubMed Web of Science ®Google Scholar
• FLEMING R, REHKA P, DESHPANDE N et al.: Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum. Reprod. (2000) 15:1440–1445.
   PubMed Web of Science ®Google Scholar
• MERVIEL PH, ANTOINE JM, BOUTLANE-IRAKI B et al.: LH concentrations after GnRH antagonist administration do not have any influence on pregnancy rates in IVF-embryo transfer. Hum. Reprod. Abstracts (2002) Num 0–007.
   Google Scholar
• NOYES N, CHUNG K, KATZ J, KREY L:Is exogenous LH necessary when using GnRH antagonists in IVF ovarian hyperstimulation? Fertil. Steil]. (2002) 76:S22.
   Google Scholar
• LOUMAYE E, ENGRAND P, SHOHAM Z,HILLIER SG, BAIRD DT: Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization Type I and Type II anovulation. Hum. Reprod. (2003) 18:314–322.
   PubMed Web of Science ®Google Scholar
• SHOHAM Z: The clinical therapeutic window for luteinising hormone in controlled ovarian stimulation. Fertil. Steil]. (2002) 77:1170–1177.
   PubMed Web of Science ®Google Scholar
• HILLIER SG: Current concepts of the roles of follicle stimulating hormone and luteinising hormone in folliculogenesis. Hum. Reprod. (1994) 9:188–191.
   PubMed Web of Science ®Google Scholar
• •The theory behind the threshold and 'ceiling effect' of LH.
   Google Scholar
• FILICORI M, COGNIGNI GE, TARABORRELLI S et al.: Luteinzing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J. Chit. Endocrinol Metab. (2001) 86:337–343.
   PubMed Web of Science ®Google Scholar
• FILICORI M, COGNIGNI GE, TARABORRELLI S et al.: Luteinising hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. Chit. Endocrinol Metab. (1999) 84:2659–2663.
   PubMed Web of Science ®Google Scholar
• FILICORI M, COGNIGNI GE, POCOGNOLI P et al: Modulation of folliculogenesis and steroidogenesis inwomen by graded menotrophin administration. Hum. Reprod. (2002) 17:2009–2015.
   PubMed Web of Science ®Google Scholar
• FILICORI M, COGNIGNI GE, TABARELLI C et al.: Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. .1 Cliii. Endocrinol. Metab. (2002) 87:1156-1161.Affiliation
   Google Scholar